BioMed Research International

Alzheimer’s Disease and Cognitive Frailty: Novel Therapeutic Technologies


Publishing date
01 Apr 2016
Status
Published
Submission deadline
13 Nov 2015

1IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

2Shanghai Institute of Geriatrics and Gerontology, Shanghai, China

3University of São Paulo, São Paulo, Brazil


Alzheimer’s Disease and Cognitive Frailty: Novel Therapeutic Technologies

Description

Alzheimer’s disease (AD) is frequently diagnosed in people over 65 years of age, although the less-prevalent early onset AD can occur much earlier. Since AD gradually renders people incapable of tending to their own needs, at present, caregiving appears to be a likely more effective means to help with the management of the disease.

During the early and moderate stages of AD, modifications to the living environment and lifestyle can increase patient safety and reduce caregiver burden. An important question refers to the relationship between quality of life and quality of care and safety in daily living activities of AD patients, considering that the home care is usually preferred by patients and families.

AD is actually considered as a continuum of disease from preclinical asymptomatic to overt, symptomatic stages. Cognitive frailty may represent a precursor of neurodegenerative processes. A potential for reversibility may also characterize this entity. A psychological component of the condition is evident and concurs at increasing the vulnerability of the individual to stressors.

Cognitive frailty refers to the heterogeneous clinical syndrome that is found in elderly individuals, excluding those with AD and other dementias, that is characterized by concurrent physical frailty and potentially reversible cognitive impairment (MCI (mild cognitive impairment)).

Risk factors for cognitive frailty and AD appear to change with age. Most of the overelderly individuals have beta-amyloid (Aβ) plaques, by extension most overelderly people have AD. Also, since most young individuals will develop Aβ deposits if they live long enough and, almost the entire population that does not already have AD is on their way to developing AD, according to the preclinical AD criteria, therefore, it is difficult to see how brain amyloidosis and brain aging could be considered separate entities arising through independent mechanisms.

The central focus of this Special Issue will be to advance novel therapeutic technologies that have shown exceptional promise in clinical models of AD and cognitive frailty. The aim will be to individualize genetic and clinic mechanisms of AD and cognitive frailty considering age-related and multidimensional approaches to the purpose of appropriate and personalized treatment, also with the use of information and communication technology (ICT) tools that can decrease the hospitalization and increase the permanence at home.

The pharmacologic treatment delivers limited symptomatic benefits, so the provision of nonpharmacological treatments in addition to standard outpatient care is an asset of good clinical practice.

Therefore prognostic evaluation of AD patients plays a key role in the decision analyses of care processes including the organization of social health care system, the support to families, caregivers, and patients as well as the choice of appropriate treatment.

Potential topics include, but are not limited to:

  • Immune regulation (e.g., chronic inflammation) of AD and cognitive frailty
  • Endocrine regulation of AD and cognitive frailty
  • Sarcopenia and AD
  • Cardiocerebral vascular disease and AD
  • The effects of emotional and affective dimensions on cognitive reserve decline
  • The multidimensional screening of AD and cognitive frailty
  • The interventions of AD and cognitive frailty
  • Secretase-based drugs in Alzheimer’s disease
  • CYP2D6 polymorphism on the efficacy of pharmacologic treatments in AD
  • Effect of other gene polymorphism on efficacy of acetylcholinesterase inhibitors in AD
  • Occupational therapy interventions for the management of behavioral and psychological symptoms of dementia
  • Cognitive and functional rehabilitation for patients with mild cognitive impairment and AD
  • Psychodynamic psychotherapy for family caregivers of AD patients
  • Technology innovation in the integrated approach to the elderly with AD

Articles

  • Special Issue
  • - Volume 2016
  • - Article ID 7242651
  • - Editorial

Alzheimer’s Disease and Cognitive Frailty: Novel Therapeutic Technologies

Grazia D’Onofrio | Zhuowei Yu | Orestes V. Forlenza
  • Special Issue
  • - Volume 2016
  • - Article ID 3245935
  • - Review Article

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease

Francesco Panza | Vincenzo Solfrizzi | ... | Giancarlo Logroscino
  • Special Issue
  • - Volume 2016
  • - Article ID 1390620
  • - Clinical Study

Influence of APOE Genotype on Alzheimer’s Disease CSF Biomarkers in a Spanish Population

J. A. Monge-Argilés | R. Gasparini-Berenguer | ... | C. Leiva-Santana
  • Special Issue
  • - Volume 2015
  • - Article ID 917156
  • - Research Article

Inhibition of ACE Retards Tau Hyperphosphorylation and Signs of Neuronal Degeneration in Aged Rats Subjected to Chronic Mild Stress

Said AbdAlla | Ahmed el Hakim | ... | Ursula Quitterer
  • Special Issue
  • - Volume 2015
  • - Article ID 218980
  • - Review Article

Nonpharmacological Interventions to Reduce Behavioral and Psychological Symptoms of Dementia: A Systematic Review

Alexandra Martini de Oliveira | Marcia Radanovic | ... | Orestes V. Forlenza
  • Special Issue
  • - Volume 2015
  • - Article ID 749451
  • - Research Article

Deep Assessment: A Novel Framework for Improving the Care of People with Very Advanced Alzheimer’s Disease

Gordon Lyons | Michael Arthur-Kelly | ... | Aimee Mavratzakis
  • Special Issue
  • - Volume 2015
  • - Article ID 481621
  • - Research Article

Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men

Cheng Ma | Jin Li | ... | Zhuowei Yu
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.